readthroughSign in
Nov 16, 2026Financing

MapLight Therapeutics sets up $100 million at-the-market stock sale facility

The company entered a sales agreement with Leerink Partners allowing it to sell up to $100 million in common stock over time through an ATM offering.

MapLight Therapeutics, Inc. disclosed in an 8-K filed for November 16, 2026, that it entered into a Sales Agreement with Leerink Partners LLC under which the company may from time to time offer and sell shares of its voting common stock through or to Leerink Partners in an at-the-market offering.1

The shares covered by the agreement will be sold under a Registration Statement on Form S-3 that the company filed on November 16, 2026, along with the related prospectus for the ATM offering.1 The prospectus permits MapLight to sell common stock with an aggregate offering price of up to $100,000,000.1

Under the terms of the deal, Leerink Partners will use commercially reasonable efforts to sell the shares based on MapLight's instructions.1 MapLight has given the agent customary indemnification rights, and Leerink Partners will earn a commission of up to 3.0% of the gross sales price for each share sold under the agreement.1

The filing notes that any sales under the agreement would be structured as "at the market offerings" as defined under Rule 415(a)(4) of the Securities Act of 1933.1 MapLight is not committed to using the facility: the company has no obligation to sell any shares under the agreement and may suspend or terminate it at any time.1

The 8-K also states that the filing itself does not constitute an offer to sell or a solicitation to buy shares in any jurisdiction where such activity would be unlawful before registration.1 The full sales agreement was filed as Exhibit 10.1, incorporated by reference from Exhibit 1.2 of the company's Form S-3 registration statement (File No. 333-300071) filed with the SEC on November 16, 2026.1

The report was signed by Christopher A. Kroeger, M.D., MapLight's Chief Executive Officer.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.